| Detected | Trial | Change |
|---|---|---|
| 2026-06-05 | NCT07213674 A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With… |
Trial sites expanded: 129 -> 133 locations |
| 2026-05-21 | NCT07493512 Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer |
Recruitment opened |
| 2026-05-21 | NCT07493512 Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer |
date change Primary completion pushed: 2027-05-27 -> 2028-01-30 |
| 2026-05-21 | NCT07493512 Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer |
date change Completion pushed: 2029-11-24 -> 2030-07-30 |
| 2026-05-16 | NCT06691984 Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy… |
overall status: "Recruiting" → "Active Not Recruiting" |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07213674 | A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With… | Metastatic Castration-resistant Prostate Cancer | Recruiting |
| NCT06691984 | Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy… | Metastatic Castration-resistant Prostate Cancer | Active, Not Recruiting |
| Phase 1 | |||
| NCT07140900 | Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination… | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Recruiting |
| NCT06613100 | Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer | Prostate Cancer | Recruiting |
| NCT04221542 | Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | Prostate Cancer | Recruiting |
| NCT07493512 | Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Recruiting |
| NCT07297979 | Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory… | Ewing Sarcoma | Recruiting |
| NCT06555796 | Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic… | Prostate Cancer | Active, Not Recruiting |